Be part of the Transformation in veterinary medicine

We love the pets around us – our dogs, cats, and horses we share our lives with. Many of us believe these animals are part of the family, providing us unconditional love and companionship throughout our lives. We have an opportunity for cutting edge treatment when disease and chronic conditions cross our path, but what happens when our animal companions encounter these same issues?

Treatment options for our companion animals shouldn’t be limited

So KindredBio is working hard to develop innovative new treatment options for the veterinary industry

  • Please provide an email address and we'll send you updates on our progress

Remember, by submitting your email address, you are agreeing to receive updated information from KindredBio!

Download the Corporate Presentation to learn more about our strategy, team, and programs.

Read the Recent News from KindredBio.

Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit

February 16, 2021/in Frontpage, Investor, News /by Katja Buhrer

SAN FRANCISCO, February 16, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this […]

Read more
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Katja Buhrer /wp-content/uploads/2017/09/KindredBioHeader2017.png Katja Buhrer2021-02-16 16:05:202021-02-16 16:05:21Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit

Kindred Biosciences Announces Two New Appointments to Board of Directors

February 9, 2021/in Frontpage, Investor, News /by Katja Buhrer

San Francisco, California (February 9, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its […]

Read more
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Katja Buhrer /wp-content/uploads/2017/09/KindredBioHeader2017.png Katja Buhrer2021-02-09 08:37:222021-02-09 08:37:23Kindred Biosciences Announces Two New Appointments to Board of Directors

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis

December 22, 2020/in Frontpage, Investor, News /by Katja Buhrer

San Francisco, California (December 22, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs. Atopic […]

Read more
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Katja Buhrer /wp-content/uploads/2017/09/KindredBioHeader2017.png Katja Buhrer2020-12-22 08:40:332020-12-22 08:40:35Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
View all press releases

Looking for More?

The Management Team

We have a world class leadership team guiding us in our quest to develop the best medicines for our best friends.

See Our Pipeline

KindredBio has an exciting pipeline of high-value products for dogs, cats, and horses in development.

News

  • Kindred Biosciences to Present at the BofA Securities Animal Health Virtual SummitFebruary 16, 2021 - 4:05 pm
  • Kindred Biosciences Announces Two New Appointments to Board of DirectorsFebruary 9, 2021 - 8:37 am
  • Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic DermatitisDecember 22, 2020 - 8:40 am

Events

  • Event: Kindred Biosciences to Present at the BofA Securities Animal Health Virtual SummitFebruary 16, 2021 - 4:12 pm
  • Event: Kindred Biosciences to Present at Stifel 2020 Virtual Healthcare ConferenceNovember 11, 2020 - 8:38 am
  • Event: Kindred Biosciences to Participate in A.G.P. Virtual Healthcare SymposiumNovember 11, 2020 - 8:37 am
$4.73 Stock is Down -0.02 (-0.42%)
KIN (Common Stock)
Previous Close Volume
$4.75 254,868
Intraday High Intraday Low
$4.92 $4.70
52 Week High 52 Week Low
$11.93 $3.11
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements
© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010
Scroll to top